Abstract:Parkinson’s disease (PD) is characterized by the degeneration of dopaminergic neurons and excessive microglial activation in the substantia nigra pars compacta (SNpc). In the present study, we aimed to demonstrate the therapeutic effectiveness of the potent sphingosine-1-phosphate receptor antagonist fingolimod (FTY720) in an animal model of PD induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), and to identify the potential mechanisms underlying these therapeutic effects. C57BL/6J mice were orally administered FTY720 before subcutaneous injection of MPTP. Open-field and rotarod tests were performed to determine the therapeutic effect of FTY720. The damage to dopaminergic neurons and the production of monoamine neurotransmitters were assessed using immunohistochemistry, high-performance liquid chromatography, and flow cytometry. Immunofluorescence (CD68- positive) and enzyme-linked immunosorbent assay were used to analyze the activation of microglia, and the levels of activated signaling molecules were measured using Western blotting. Our findings indicated that FTY720 significantly attenuated MPTP-induced behavioral deficits, reduced the loss of dopaminergic neurons, and increased dopamine release. FTY720 directly inhibited MPTP-induced microglial activation in the SNpc, suppressed the production of interleukin (IL)-6, IL-1β, and tumor necrosis factor-α in BV-2 microglial cells treated with 1-methyl-4-phenylpyridinium (MPP + ), and subsequently decreased apoptosis in SH-SY5Y neuroblastoma cells. Moreover, in MPP + -treated BV-2 cells and primary microglia, FTY720 treatment significantly attenuated the increases in the phosphorylation of PI3K/AKT/GSK-3β, reduced ROS generation and p65 activation, and also inhibited the activation of NLRP3 inflammasome and caspase-1. In conclusion, FTY720 may reduce PD progression by inhibiting NLRP3 inflammasome activation via its effects on ROS generation and p65 activation in microglia. These findings provide novel insights into the mechanisms underlying the therapeutic effects of FTY720, suggesting its potential as a novel therapeutic strategy against PD. Graphical Abstract FTY720 may reduce ROS production by inhibiting the PI3K/AKT/GSK-3β signaling pathway, while at the same time reducing p65 phosphorylation, thus decreasing NLRP3 inflammasome activation through these two pathways, ultimately reducing microglia activation-induced neuronal damage.

PI3-K/Akt and ERK pathways activated by VEGF play opposite roles in MPP+-induced neuronal apoptosis.

Gene Expression Profiling of MPP+-treated MN9D Cells: A Mechanism of Toxicity Study

VEGF-induced Activation of the PI3-K/Akt Pathway Reduces Mutant SOD1-mediated Motor Neuron Cell Death.

Vascular Endothelial Growth Factor Protects PC12 Cells Against 6-Hydroxydopamine-induced Degeneration Through Receptor Neuropilin-1

Valproic Acid Protects Primary Dopamine Neurons from MPP+-Induced Neurotoxicity: Involvement of GSK3β Phosphorylation by Akt and ERK Through the Mitochondrial Intrinsic Apoptotic Pathway

Cystatin C As a Potential Therapeutic Mediator Against Parkinson’s Disease Via VEGF-induced Angiogenesis and Enhanced Neuronal Autophagy in Neurovascular Units

FTY720 Inhibits MPP+-Induced Microglial Activation by Affecting NLRP3 Inflammasome Activation

ERK inhibition reduces neuronal death and ameliorates inflammatory responses in forebrain-specific Ppp2c alpha knockout mice

Neuroprotective Effects of the DPP4 Inhibitor Vildagliptin in In Vivo and In Vitro Models of Parkinson’s Disease

Molecular Mechanism of Platelet-Derived Growth Factor (PDGF)-BB-Mediated Protection Against MPP+ Toxicity in SH-SY5Y Cells

N-Propargyl Caffeamide (PACA) Ameliorates Dopaminergic Neuronal Loss and Motor Dysfunctions in MPTP Mouse Model of Parkinson’s Disease and in MPP+-Induced Neurons via Promoting the Conversion of proNGF to NGF

Implication of the c-Jun-NH2-terminal kinase pathway in the neuroprotective effect of puerarin against 1-methyl-4-phenylpyridinium (MPP+)-induced apoptosis in PC-12 cells

VEGF attenuates 2-VO induced cognitive impairment and neuronal injury associated with the activation of PI3K/Akt and Notch1 pathway.

Peroxisome Proliferator-Activated Receptor γ Coactivator 1α Activates Vascular Endothelial Growth Factor That Protects Against Neuronal Cell Death Following Status Epilepticus through PI3K/AKT and MEK/ERK Signaling

Marine-Derived Xyloketal Compound Ameliorates MPP+-Induced Neuronal Injury Through Regulating of the IRE1/XBP1 Signaling Pathway.

Protective Effect of Fucoidan Against MPP+-Induced SH-SY5Y Cells Apoptosis by Affecting the PI3K/Akt Pathway

Survival effect of PDGF-CC rescues neurons from apoptosis in both brain and retina by regulating GSK3beta phosphorylation.

MiR-135a-5p and Mst1 regulate MPP + -1 induced apoptosis and autophagy in Parkinson's disease model in vitro

Polylysine-modified Polyethylenimine (PEI-PLL) Mediated VEGF Gene Delivery Protects Dopaminergic Neurons in Cell Culture and in Rat Models of Parkinson's Disease (PD).

Molecular and Cellular Mechanisms of Neuroprotection by Vascular Endothelial Growth Factor.

Neuroprotective Effects of Cordycepin on MPTP-induced Parkinson's Disease Mice Via Suppressing PI3K/AKT/mTOR and MAPK-mediated Neuroinflammation